Which is more effective, rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Analysis from the British Society for Rheumatology Biologics Register.

M Soliman, K Hyrich, M Lunt, K Watson, D Symmons, D. Ashcroft

    Research output: Chapter in Book/Report/Conference proceedingConference contribution

    Original languageEnglish
    Title of host publicationPharmacoepidemiology and Drug Safety; 20: S13
    PublisherJohn Wiley & Sons Ltd
    Publication statusPublished - 2011

    Cite this